{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:05:02Z","timestamp":1790845502606,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003086","name":"Eusko Jaurlaritza","doi-asserted-by":"publisher","award":["BFI-2011-9"],"award-info":[{"award-number":["BFI-2011-9"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Resistance to antibiotics poses a major global threat according to the World Health Organization. Restoring the activity of existing drugs is an attractive alternative to address this challenge. One of the most efficient mechanisms of bacterial resistance involves the expression of efflux pump systems capable of expelling antibiotics from the cell. Although there are efflux pump inhibitors (EPIs) available, these molecules are toxic for humans. We hypothesized that permeability-increasing antimicrobial peptides (AMPs) could lower the amount of EPI necessary to sensitize bacteria to antibiotics that are efflux substrates. To test this hypothesis, we measured the ability of polymyxin B nonapeptide (PMBN), to synergize with antibiotics in the presence of EPIs. Assays were performed using planktonic and biofilm-forming cells of\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    strains overexpressing the MexAB-OprM efflux system. Synergy between PMBN and EPIs boosted azithromycin activity by a factor of 2,133 and sensitized\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    to all tested antibiotics. This reduced several orders of magnitude the amount of inhibitor needed for antibiotic sensitization. The selected antibiotic-EPI-PMBN combination caused a 10 million-fold reduction in the viability of biofilm forming cells. We proved that AMPs can synergize with EPIs and that this phenomenon can be exploited to sensitize bacteria to antibiotics.\n                  <\/jats:p>","DOI":"10.1038\/s41598-019-39659-4","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T06:05:48Z","timestamp":1551765948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["A permeability-increasing drug synergizes with bacterial efflux pump inhibitors and restores susceptibility to antibiotics in multi-drug resistant Pseudomonas aeruginosa strains"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5711-5349","authenticated-orcid":false,"given":"Raquel","family":"Ferrer-Espada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawraa","family":"Shahrour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsey","family":"Pitts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"S\u00e1nchez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3755-451X","authenticated-orcid":false,"given":"Guillermo","family":"Mart\u00ednez-de-Tejada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,5]]},"reference":[{"key":"39659_CR1","unstructured":"World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 1\u20137 (2017)."},{"key":"39659_CR2","unstructured":"European Centre for Disease Prevention and Control. Annual epidemiological report 2014. 1\u201328 (2015)."},{"key":"39659_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1128\/CMR.00068-09","volume":"23","author":"JJ Lipuma","year":"2010","unstructured":"Lipuma, J. J. The changing microbial epidemiology in cystic fibrosis. Clin. Microbiol. Rev. 23, 299\u2013323 (2010).","journal-title":"Clin. Microbiol. Rev."},{"key":"39659_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fmicb.2011.00065","volume":"2","author":"K Poole","year":"2011","unstructured":"Poole, K. Pseudomonas aeruginosa: resistance to the max. Front. Microbio. 2, 65 (2011).","journal-title":"Front. Microbio."},{"key":"39659_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fcimb.2017.00039","volume":"7","author":"MF Moradali","year":"2017","unstructured":"Moradali, M. F., Ghods, S. & Rehm, B. H. A. Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. Frontiers in cellular and infection microbiology 7, 39 (2017).","journal-title":"Frontiers in cellular and infection microbiology"},{"key":"39659_CR6","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1128\/MMBR.00013-14","volume":"78","author":"D Lebeaux","year":"2014","unstructured":"Lebeaux, D., Ghigo, J.-M. & Beloin, C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol. Mol. Biol. Rev. 78, 510\u2013543 (2014).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"39659_CR7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1476-5381.2011.01250.x","volume":"163","author":"ARM Coates","year":"2011","unstructured":"Coates, A. R. M., Halls, G. & Hu, Y. Novel classes of antibiotics or more of the same? Br. J. Pharmacol. 163, 184\u2013194 (2011).","journal-title":"Br. J. Pharmacol."},{"key":"39659_CR8","unstructured":"World Health Organization. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including Mycobacterium tuberculosis. 1\u201348 (2017)."},{"key":"39659_CR9","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.2174\/138161211795703726","volume":"17","author":"GP Tegos","year":"2011","unstructured":"Tegos, G. P. et al. Microbial efflux pump inhibition: tactics and strategies. Curr. Pharm. Des. 17, 1291\u20131302 (2011).","journal-title":"Curr. Pharm. Des."},{"key":"39659_CR10","doi-asserted-by":"publisher","first-page":"7376","DOI":"10.1128\/AEM.01310-08","volume":"74","author":"M Kvist","year":"2008","unstructured":"Kvist, M., Hancock, V. & Klemm, P. Inactivation of efflux pumps abolishes bacterial biofilm formation. Appl. Environ. Microbiol. 74, 7376\u20137382 (2008).","journal-title":"Appl. Environ. Microbiol."},{"key":"39659_CR11","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1128\/AAC.49.9.3858-3867.2005","volume":"49","author":"RJ Gillis","year":"2005","unstructured":"Gillis, R. J. et al. Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrobi Agents and Chemother 49, 3858\u20133867 (2005).","journal-title":"Antimicrobi Agents and Chemother"},{"key":"39659_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/157489106777452692","volume":"1","author":"F Van Bambeke","year":"2006","unstructured":"Van Bambeke, F., Pag\u00e8s, J. & Lee, V. J. Inhibitors of bacterial efflux pumps as adjuvants in antibiotic treatments and diagnostic tools for detection of resistance by efflux. Recent Pat Antiinfect Drug Discov 1, 157\u2013175 (2006).","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"39659_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1128\/CMR.00043-12","volume":"25","author":"L Fern\u00e1ndez","year":"2012","unstructured":"Fern\u00e1ndez, L. & Hancock, R. E. W. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin. Microbiol. Rev. 25, 661\u2013681 (2012).","journal-title":"Clin. Microbiol. Rev."},{"key":"39659_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1128\/AAC.45.1.105-116.2001","volume":"45","author":"O Lomovskaya","year":"2001","unstructured":"Lomovskaya, O. et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrobi Agents and Chemother 45, 105\u2013116 (2001).","journal-title":"Antimicrobi Agents and Chemother"},{"key":"39659_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1128\/CMR.00117-14","volume":"28","author":"X-Z Li","year":"2015","unstructured":"Li, X.-Z., Pl\u00e9siat, P. & Nikaido, H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin. Microbiol. Rev. 28, 337\u2013418 (2015).","journal-title":"Clin. Microbiol. Rev."},{"key":"39659_CR16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1517\/17460441.2012.688949","volume":"7","author":"HP Schweizer","year":"2012","unstructured":"Schweizer, H. P. Understanding efflux in Gram-negative bacteria: opportunities for drug discovery. Expert Opin Drug Discov 7, 633\u2013642 (2012).","journal-title":"Expert Opin Drug Discov"},{"key":"39659_CR17","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.bcp.2005.12.008","volume":"71","author":"O Lomovskaya","year":"2006","unstructured":"Lomovskaya, O. & Bostian, K. A. Practical applications and feasibility of efflux pump inhibitors in the clinic-a vision for applied use. Biochem. Pharmacol. 71, 910\u2013918 (2006).","journal-title":"Biochem. Pharmacol."},{"key":"39659_CR18","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1128\/AAC.49.2.849-852.2005","volume":"49","author":"JA Bohnert","year":"2005","unstructured":"Bohnert, J. A. & Kern, W. V. Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. Antimicrobi Agents and Chemother 49, 849\u2013852 (2005).","journal-title":"Antimicrobi Agents and Chemother"},{"key":"39659_CR19","doi-asserted-by":"publisher","unstructured":"Chihara, S., Tobita, T., Yahata, M., Ito, A. & Koyama, Y. Enzymatic degradation of colistin isolation and identification of \u03b1-N-acyl \u03b1,\u03b3-diaminobutyric acid and colistin nonapeptide. Agric. Biol. Chem., https:\/\/doi.org\/10.1080\/00021369.1973.10861030 (1973).","DOI":"10.1080\/00021369.1973.10861030"},{"key":"39659_CR20","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1128\/AAC.49.8.3122-3128.2005","volume":"49","author":"H Tsubery","year":"2005","unstructured":"Tsubery, H. et al. Neopeptide antibiotics that function as opsonins and membrane-permeabilizing agents for gram-negative bacteria. Antimicrobi Agents and Chemother 49, 3122\u20133128 (2005).","journal-title":"Antimicrobi Agents and Chemother"},{"key":"39659_CR21","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1021\/acs.chemrestox.5b00262","volume":"28","author":"A Nilsson","year":"2015","unstructured":"Nilsson, A. et al. Investigating nephrotoxicity of polymyxin derivatives by mapping renal distribution using mass spectrometry imaging. Chem. Res. Toxicol. 28, 1823\u20131830 (2015).","journal-title":"Chem. Res. Toxicol."},{"key":"39659_CR22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/toxsci\/kft247","volume":"137","author":"ND Keirstead","year":"2014","unstructured":"Keirstead, N. D. et al. Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers. Toxicol. Sci. 137, 278\u2013291 (2014).","journal-title":"Toxicol. Sci."},{"key":"39659_CR23","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1128\/AAC.25.6.701","volume":"25","author":"P Viljanen","year":"1984","unstructured":"Viljanen, P. & Vaara, M. Susceptibility of gram-negative bacteria to polymyxin B nonapeptide. Antimicrobi Agents and Chemother 25, 701\u2013705 (1984).","journal-title":"Antimicrobi Agents and Chemother"},{"key":"39659_CR24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1128\/AAC.00904-10","volume":"55","author":"S S\u00e1nchez-G\u00f3mez","year":"2011","unstructured":"S\u00e1nchez-G\u00f3mez, S. et al. Structural features governing the activity of lactoferricin-derived peptides that act in synergy with antibiotics against Pseudomonas aeruginosa in vitro and in vivo. Antimicrobi Agents and Chemother 55, 218\u2013228 (2011).","journal-title":"Antimicrobi Agents and Chemother"},{"key":"39659_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/1471-2180-8-196","volume":"8","author":"S S\u00e1nchez-G\u00f3mez","year":"2008","unstructured":"S\u00e1nchez-G\u00f3mez, S. et al. Comparative analysis of selected methods for the assessment of antimicrobial and membrane-permeabilizing activity: a case study for lactoferricin derived peptides. BMC Microbiol 8, 196 (2008).","journal-title":"BMC Microbiol"},{"key":"39659_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S0924-8579(03)00119-5","volume":"22","author":"MC Conejo","year":"2003","unstructured":"Conejo, M. C., Mart\u00ednez-Mart\u00ednez, L., Garc\u00eda, I., Picabea, L. & Pascual, \u00c1. Effect of siliconized latex urinary catheters on the activity of carbapenems against Pseudomonas aeruginosa strains with defined mutations in ampC, oprD, and genes coding for efflux systems. Int. J. Antimicrob. Agents 22, 122\u2013127 (2003).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"39659_CR27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1128\/AAC.42.2.399","volume":"42","author":"X Li","year":"1998","unstructured":"Li, X., Zhang, L., Srikumar, R. & Poole, K. \u03b2-lactamase inhibitors are substrates for the multidrug efflux pumps of Pseudomonas aeruginosa. Antimicrobi Agents and Chemother 42, 399\u2013403 (1998).","journal-title":"Antimicrobi Agents and Chemother"},{"key":"39659_CR28","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1128\/AAC.44.12.3322-3327.2000","volume":"44","author":"N Masuda","year":"2000","unstructured":"Masuda, N. et al. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrobi Agents and Chemother 44, 3322\u20133327 (2000).","journal-title":"Antimicrobi Agents and Chemother"},{"key":"39659_CR29","unstructured":"S\u00e1nchez-G\u00f3mez, S. Potenciaci\u00f3n de antibi\u00f3ticos mediante p\u00e9ptidos cati\u00f3nicos permeabilizantes: aplicaci\u00f3n al desarrollo de terapias frente a la sepsis debida a Pseudomonas aeruginosa multiresistente. 1\u2013302 (Universidad de Navarra, 2008)."},{"key":"39659_CR30","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1128\/AAC.01011-06","volume":"51","author":"N Hoffmann","year":"2007","unstructured":"Hoffmann, N. et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(\u2212\/\u2212) mice. Antimicrobi Agents and Chemother 51, 3677\u20133687 (2007).","journal-title":"Antimicrobi Agents and Chemother"},{"key":"39659_CR31","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1378\/chest.128.2.912","volume":"128","author":"T Wagner","year":"2005","unstructured":"Wagner, T., Soong, G., Sokol, S., Saiman, L. & Prince, A. Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. Chest 128, 912\u2013919 (2005).","journal-title":"Chest"},{"key":"39659_CR32","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1128\/AAC.45.6.1930-1933.2001","volume":"45","author":"K Tateda","year":"2001","unstructured":"Tateda, K. et al. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrobi Agents and Chemother 45, 1930\u20131933 (2001).","journal-title":"Antimicrobi Agents and Chemother"},{"key":"39659_CR33","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/jac\/dkg397","volume":"52","author":"S Favre-Bont\u00e9","year":"2003","unstructured":"Favre-Bont\u00e9, S., K\u00f6hler, T. & Van Delden, C. Biofilm formation by Pseudomonas aeruginosa: role of the C4-HSL cell-to-cell signal and inhibition by azithromycin. J. Antimicrob. Chemother. 52, 598\u2013604 (2003).","journal-title":"J. Antimicrob. Chemother."},{"key":"39659_CR34","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/jac\/dki445","volume":"57","author":"WV Kern","year":"2006","unstructured":"Kern, W. V. et al. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J. Antimicrob. Chemother. 57, 339\u2013343 (2006).","journal-title":"J. Antimicrob. Chemother."},{"key":"39659_CR35","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/jac\/dkl081","volume":"57","author":"S Pannek","year":"2006","unstructured":"Pannek, S. et al. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide. J. Antimicrob. Chemother. 57, 970\u2013974 (2006).","journal-title":"J. Antimicrob. Chemother."},{"key":"39659_CR36","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.bbapap.2008.11.005","volume":"1794","author":"AH Delcour","year":"2009","unstructured":"Delcour, A. H. Outer membrane permeability and antibiotic resistance. Biochim. Biophys. Acta 1794, 808\u2013816 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"39659_CR37","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1128\/JB.02456-14","volume":"197","author":"R Misra","year":"2015","unstructured":"Misra, R., Morrison, K. D., Cho, H. J. & Khuu, T. Importance of Real-Time Assays To Distinguish Multidrug Efflux Pump-Inhibiting and Outer Membrane-Destabilizing Activities in Escherichia coli. J. Bacteriol. 197, 2479\u20132488 (2015).","journal-title":"J. Bacteriol."},{"key":"39659_CR38","doi-asserted-by":"publisher","first-page":"e60666","DOI":"10.1371\/journal.pone.0060666","volume":"8","author":"RP Lamers","year":"2013","unstructured":"Lamers, R. P., Cavallari, J. F. & Burrows, L. L. The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PA\u03b2N) permeabilizes the outer membrane of gram-negative bacteria. PLoS ONE 8, e60666 (2013).","journal-title":"PLoS ONE"},{"key":"39659_CR39","doi-asserted-by":"publisher","first-page":"6224","DOI":"10.1128\/AAC.03283-14","volume":"58","author":"AV Vargiu","year":"2014","unstructured":"Vargiu, A. V., Ruggerone, P., Opperman, T. J., Nguyen, S. T. & Nikaido, H. Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other inhibitors. Antimicrobi Agents and Chemother 58, 6224\u20136234 (2014).","journal-title":"Antimicrobi Agents and Chemother"},{"key":"39659_CR40","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/jac\/10.4.259","volume":"10","author":"PM Shah","year":"1982","unstructured":"Shah, P. M. Paradoxical effect of antibiotics. I. The \u2018Eagle effect\u2019. J. Antimicrob. Chemother. 10, 259\u2013260 (1982).","journal-title":"J. Antimicrob. Chemother."},{"key":"39659_CR41","doi-asserted-by":"publisher","first-page":"7786","DOI":"10.1128\/AAC.01476-15","volume":"59","author":"M Wu","year":"2015","unstructured":"Wu, M., Tan, J. & Dick, T. Eagle Effect in Nonreplicating Persister Mycobacteria. Antimicrobi Agents and Chemother 59, 7786\u20137789 (2015).","journal-title":"Antimicrobi Agents and Chemother"},{"key":"39659_CR42","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1128\/AAC.45.6.1761-1770.2001","volume":"45","author":"TR De Kievit","year":"2001","unstructured":"De Kievit, T. R. et al. Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrobi Agents and Chemother 45, 1761\u20131770 (2001).","journal-title":"Antimicrobi Agents and Chemother"},{"key":"39659_CR43","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1128\/AAC.50.4.1463-1469.2006","volume":"50","author":"MA Jabra-Rizk","year":"2006","unstructured":"Jabra-Rizk, M. A., Meiller, T. F., James, C. E. & Shirtliff, M. E. Effect of farnesol on Staphylococcus aureus biofilm formation and antimicrobial susceptibility. Antimicrobi Agents and Chemother 50, 1463\u20131469 (2006).","journal-title":"Antimicrobi Agents and Chemother"},{"key":"39659_CR44","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1128\/AEM.00142-06","volume":"72","author":"H-L Alakomi","year":"2006","unstructured":"Alakomi, H.-L., Paananen, A., Suihko, M.-L., Helander, I. M. & Saarela, M. Weakening effect of cell permeabilizers on gram-negative bacteria causing biodeterioration. Appl. Environ. Microbiol. 72, 4695\u20134703 (2006).","journal-title":"Appl. Environ. Microbiol."},{"key":"39659_CR45","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00253-010-2748-3","volume":"88","author":"C Nagant","year":"2010","unstructured":"Nagant, C. et al. Interaction between tobramycin and CSA-13 on clinical isolates of Pseudomonas aeruginosa in a model of young and mature biofilms. Appl. Microbiol. Biotechnol. 88, 251\u2013263 (2010).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"39659_CR46","doi-asserted-by":"publisher","first-page":"e63158","DOI":"10.1371\/journal.pone.0063158","volume":"8","author":"LR Marks","year":"2013","unstructured":"Marks, L. R., Clementi, E. A. & Hakansson, A. P. Sensitization of Staphylococcus aureus to methicillin and other antibiotics in vitro and in vivo in the presence of HAMLET. PLoS ONE 8, e63158 (2013).","journal-title":"PLoS ONE"},{"key":"39659_CR47","doi-asserted-by":"publisher","unstructured":"Doke, S. K., Raut, J. S., Dhawale, S. & Karuppayil, S. M. Sensitization of Candida albicans biofilms to fluconazole by terpenoids of plant origin. J. Gen. Appl. Microbiol., https:\/\/doi.org\/10.2323\/jgam.60.163 (2014).","DOI":"10.2323\/jgam.60.163"},{"key":"39659_CR48","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1128\/AAC.00092-15","volume":"59","author":"SM Ribeiro","year":"2015","unstructured":"Ribeiro, S. M. et al. Antibiofilm peptides increase the susceptibility of carbapenemase-producing Klebsiella pneumoniae clinical isolates to \u03b2-lactam antibiotics. Antimicrobi Agents and Chemother 59, 3906\u20133912 (2015).","journal-title":"Antimicrobi Agents and Chemother"},{"key":"39659_CR49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1586\/14787210.2014.863148","volume":"12","author":"N Fern\u00e1ndez-Hidalgo","year":"2014","unstructured":"Fern\u00e1ndez-Hidalgo, N. & Almirante, B. Antibiotic-lock therapy: a clinical viewpoint. Expert Rev Anti Infect Ther 12, 117\u2013129 (2014).","journal-title":"Expert Rev Anti Infect Ther"},{"key":"39659_CR50","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement M100-S21. (CLSI, Wayne, PA, USA, 2011)."},{"key":"39659_CR51","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1128\/AAC.01645-10","volume":"55","author":"G Cabot","year":"2011","unstructured":"Cabot, G. et al. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrobi Agents and Chemother 55, 1906\u20131911 (2011).","journal-title":"Antimicrobi Agents and Chemother"},{"key":"39659_CR52","doi-asserted-by":"publisher","first-page":"e0126479","DOI":"10.1371\/journal.pone.0126479","volume":"10","author":"C Stein","year":"2015","unstructured":"Stein, C. et al. Three Dimensional Checkerboard Synergy Analysis of Colistin, Meropenem, Tigecycline against Multidrug-Resistant Clinical Klebsiella pneumonia Isolates. Plos One 10, e0126479 (2015).","journal-title":"Plos One"},{"key":"39659_CR53","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/infdis\/137.2.122","volume":"137","author":"MC Berenbaum","year":"1978","unstructured":"Berenbaum, M. C. A method for testing for synergy with any number of agents. J Infect Dis 137, 122\u2013130 (1978).","journal-title":"J Infect Dis"},{"key":"39659_CR54","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0167-7012(00)00122-6","volume":"40","author":"S Stepanovi\u0107","year":"2000","unstructured":"Stepanovi\u0107, S., Vukovic, D., Dakic, I., Savi\u0107, B. & Svabi\u0107-Vlahovi\u0107, M. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J. Microbiol. Methods 40, 175\u2013179 (2000).","journal-title":"J. Microbiol. Methods"},{"key":"39659_CR55","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12866-015-0473-x","volume":"15","author":"S S\u00e1nchez-G\u00f3mez","year":"2015","unstructured":"S\u00e1nchez-G\u00f3mez, S. et al. Antimicrobial activity of synthetic cationic peptides and lipopeptides derived from human lactoferricin against Pseudomonas aeruginosa planktonic cultures and biofilms. BMC Microbiol 15, 137 (2015).","journal-title":"BMC Microbiol"},{"key":"39659_CR56","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/08927019409378264","volume":"8","author":"FP Yu","year":"1994","unstructured":"Yu, F. P., Callis, G. M., Stewart, P. S., Griebe, T. & Mcfeters, G. A. Cryosectioning of biofilms for microscopic examination. Biofouling 8, 85\u201391 (1994).","journal-title":"Biofouling"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39659-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39659-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39659-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T02:03:42Z","timestamp":1671242622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39659-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,5]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["39659"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-39659-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,5]]},"assertion":[{"value":"22 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3452"}}